Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Accumulated Expenses (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Accumulated Expenses for 12 consecutive years, with $10.2 million as the latest value for Q1 2026.

  • For Q1 2026, Accumulated Expenses rose 10.48% year-over-year to $10.2 million; the TTM value through Mar 2026 reached $10.2 million, up 10.48%, while the annual FY2025 figure was $9.5 million, 21.35% down from the prior year.
  • Accumulated Expenses hit $10.2 million in Q1 2026 for Cartesian Therapeutics, up from $9.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $15.6 million in Q4 2023 and bottomed at $7.7 million in Q3 2025.
  • Average Accumulated Expenses over 5 years is $10.9 million, with a median of $10.2 million recorded in 2026.
  • Year-over-year, Accumulated Expenses skyrocketed 39.56% in 2022 and then tumbled 30.69% in 2024.
  • Cartesian Therapeutics' Accumulated Expenses stood at $14.1 million in 2022, then increased by 10.57% to $15.6 million in 2023, then fell by 22.45% to $12.1 million in 2024, then dropped by 21.35% to $9.5 million in 2025, then rose by 6.98% to $10.2 million in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $10.2 million, $9.5 million, and $7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.